Enliven Therapeutics, Inc. Total Equity
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
| Total Equity | $8,737.0K | $5,873.0K | $28.9M | ($20.3M) | ($42.9M) | ($76.8M) | $245.9M |
Enliven Therapeutics, Inc. (ELVN) Total Equity comparison analysis
General
LTM Total Equity
Growth
Company name
YoY growth
3Y CAGR
5Y CAGR
ELVN key stats
| Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
|---|---|---|---|---|---|---|---|
% growth | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% | 0.0 0.0% |
| Cost of Goods Sold (COGS) | 0.0 | 0.0 | 0.0 | 0.1 | 0.1 | 0.6 | 0.3 |
% margin | 0.0 0.0% | 0.0 0.0% | (0.0) 0.0% | (0.1) 0.0% | (0.1) 0.0% | (0.6) 0.0% | (0.3) 0.0% |
| Operating Expenses | 8.9 | 10.7 | 24.1 | 9.3 | 24.8 | 38.8 | 83.5 |
| Research & Development Expenses (R&D) | 7.9 | 8.2 | 19.0 | 8.2 | 20.5 | 31.0 | 64.6 |
| Selling, General & Administrative Expenses (SG&A) | 1.0 | 2.4 | 5.1 | 1.1 | 4.3 | 7.8 | 19.0 |
% margin | (8.9) 0.0% | (10.7) 0.0% | (24.1) 0.0% | (9.3) 0.0% | (24.8) 0.0% | (38.8) 0.0% | (83.5) 0.0% |
| Interest Income | 0.0 | 0.0 | 0.6 | 0.0 | 0.0 | 1.1 | 12.0 |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Pre-tax Income | 0.2 | (11.3) | (23.5) | (19.0) | (24.7) | (37.7) | (71.6) |
% effective tax rate | 0.2 100.0% | (0.8) 7.2% | 0.7 (2.8%) | (0.0) 0.2% | (0.0) 0.1% | 0.1 (0.2%) | 0.0 0.0% |
% margin | 0.0 0.0% | (11.3) 0.0% | (23.5) 0.0% | (18.9) 0.0% | (24.7) 0.0% | (37.8) 0.0% | (71.6) 0.0% |
| EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
| Diluted EPS | 0.00 | (2.62) | (5.43) | (14.14) | (3.17) | (6.03) | (2.01) |
% margin | 0.2 0.0% | (11.3) 0.0% | (23.4) 0.0% | (9.3) 0.0% | (24.6) 0.0% | (38.6) 0.0% | (81.9) 0.0% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
FAQ
1) What is Enliven Therapeutics, Inc.'s Total Equity?
As of today, Enliven Therapeutics, Inc.'s last 12-month Total Equity is $288.4M, based on the financial report for Sep 30, 2024 (Q3’2024).
2) What is Enliven Therapeutics, Inc.'s Total Equity growth rate?
Over the last year, Enliven Therapeutics, Inc.'s Total Equity growth was 10.2%. The average annual Total Equity growth rates for Enliven Therapeutics, Inc. have been 56.3% over the past three years, N/A over the past five years.
3) Is Enliven Therapeutics, Inc.'s Total Equity growth rate Good?
Over the last year, Enliven Therapeutics, Inc.'s Total Equity growth was 10.2%, which is higher than industry growth of (0.2%). It indicates that Enliven Therapeutics, Inc.'s Total Equity growth is Good.